Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492656 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL14884383 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL18344600 | 0.88 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL12992164 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2USP2RECQLHSD17B10ATM | |
| SCHEMBL13804186 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL15116754 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL185522 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL154453 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL186174 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2RECQLHSD17B10CA12 | |
| SCHEMBL16604806 | 0.82 | SMN1; SMN2 (0.49) | SMN1; SMN2USP2RECQLHSD17B10CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-114945366-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220153756-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2022-05-19 | — | — | US | disclosed |
| EP-3157904-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2020-11-18 | — | — | EP | disclosed |
| US-20170121349-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2017-05-04 | — | — | US | disclosed |
| WO-2015193506-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2015-12-23 | — | — | WO | disclosed |
| CN-101801962-A | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases | ASTRAZENECA AB | 2010-08-11 | — | — | CN | disclosed |
| EP-2074118-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2009-07-01 | — | — | EP | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20090018134-A1 | Compounds - 945 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007748-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153756-A1 | ANTI-INFECTIVE COMPOUNDS | RABGGTB, ELANE, SERPINB1 | SMN1; SMN2 4839/4885USP2 3826/4885RECQL 1917/4885 |
| US-20090018134-A1 | Compounds - 945 | MTOR, PIK3CA, PIK3R5 | SMN1; SMN2 2003/4885USP2 4635/4885RECQL 1648/4885 |
| US-20170121349-A1 | Anti-Infective Compounds | FNTB, LSS, PGLS | SMN1; SMN2 4810/4885USP2 4482/4885RECQL 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.